Eidos Therapeutics, Inc. announced earnings results for the second quarter ended June 30, 2019. For the second quarter, the company announced operating loss was USD 14.794 million compared to USD 8.089 million a year ago. Net loss was USD 14.053 million compared to USD 11.381 million a year ago. Basic loss per share was USD 0.39 compared to USD 1.4 a year ago. For the half year, operating loss was USD 27.378 million compared to USD 16.086 million a year ago. Net loss was USD 25.786 million compared to USD 19.344 million a year ago. Basic loss per share was USD 0.71 compared to USD 3.06 a year ago.